Vincerx Pharma Performance dei guadagni passati
Il passato criteri di controllo 0/6
Vincerx Pharma's earnings have been declining at an average annual rate of -24.1%, while the Biotechs industry saw earnings growing at 19% annually.
Informazioni chiave
-24.1%
Tasso di crescita degli utili
-5.0%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | n/a |
| Rendimento del capitale proprio | -182.5% |
| Margine netto | n/a |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Ripartizione dei ricavi e delle spese
Come Vincerx Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -28 | 12 | 18 |
| 31 Mar 24 | 0 | -38 | 12 | 23 |
| 31 Dec 23 | 0 | -40 | 14 | 29 |
| 30 Sep 23 | 0 | -47 | 16 | 35 |
| 30 Jun 23 | 0 | -54 | 17 | 39 |
| 31 Mar 23 | 0 | -61 | 18 | 45 |
| 31 Dec 22 | 0 | -63 | 19 | 50 |
| 30 Sep 22 | 0 | -58 | 20 | 53 |
| 30 Jun 22 | 0 | -66 | 21 | 54 |
| 31 Mar 22 | 0 | -49 | 23 | 51 |
| 31 Dec 21 | 0 | -39 | 23 | 40 |
| 30 Sep 21 | 0 | -49 | 20 | 30 |
| 30 Jun 21 | 0 | -25 | 15 | 18 |
| 31 Mar 21 | 0 | -23 | 8 | 7 |
| 31 Dec 20 | 0 | -17 | 4 | 2 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
Guadagni di qualità: VINC is currently unprofitable.
Margine di profitto in crescita: VINC is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: VINC is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.
Accelerare la crescita: Unable to compare VINC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: VINC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: VINC has a negative Return on Equity (-182.51%), as it is currently unprofitable.